Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Barry

Showing results (631-640 of 674) with videos related to

Pageof 68
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2016
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast CancerMelinda L Telli, Kirsten M Timms, Julia Reid, et al.
Cell Reports|May 3, 2018
CSF1R<sup>+</sup> Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous SubtypeJuliana B Candido, Jennifer P Morton, Peter Bailey, et al.
Communications Medicine|January 13, 2026
Probing intratumoral metabolic compartmentalisation in a patient with fumarate hydratase-deficient renal cancer using clinical hyperpolarised <sup>13</sup>C-MRI and mass spectrometry imagingInes Horvat-Menih, Ruth Casey, James Denholm, et al.
Cancer Research|May 19, 2005
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerStephen R Wedge, Jane Kendrew, Laurent F Hennequin, et al.
Molecular Cancer Therapeutics|July 18, 2013
AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivoSarah A Loddick, Sarah J Ross, Andrew G Thomason, et al.
Cancer Cell|September 19, 2019
Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and MetastasisRene Jackstadt, Sander R van Hooff, Joshua D Leach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid TumorsAtish D Choudhury, Celestia S Higano, Johann S de Bono, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2019
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast CancerSara M Tolaney, Hao Guo, Sonia Pernas, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 6, 2020
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus NephritisYemil Atisha-Fregoso, Susan Malkiel, Kristina M Harris, et al.
Journal of the National Cancer Institute|June 30, 2014
Therapeutic targeting of integrin αvβ6 in breast cancerKate M Moore, Gareth J Thomas, Stephen W Duffy, et al.
Pageof 68

Showing results (631-640 of 674) with videos related to

Sort By:
Pageof 68
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2016
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast CancerMelinda L Telli, Kirsten M Timms, Julia Reid, et al.
Cell Reports|May 3, 2018
CSF1R<sup>+</sup> Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous SubtypeJuliana B Candido, Jennifer P Morton, Peter Bailey, et al.
Communications Medicine|January 13, 2026
Probing intratumoral metabolic compartmentalisation in a patient with fumarate hydratase-deficient renal cancer using clinical hyperpolarised <sup>13</sup>C-MRI and mass spectrometry imagingInes Horvat-Menih, Ruth Casey, James Denholm, et al.
Cancer Research|May 19, 2005
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerStephen R Wedge, Jane Kendrew, Laurent F Hennequin, et al.
Molecular Cancer Therapeutics|July 18, 2013
AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivoSarah A Loddick, Sarah J Ross, Andrew G Thomason, et al.
Cancer Cell|September 19, 2019
Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and MetastasisRene Jackstadt, Sander R van Hooff, Joshua D Leach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid TumorsAtish D Choudhury, Celestia S Higano, Johann S de Bono, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2019
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast CancerSara M Tolaney, Hao Guo, Sonia Pernas, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 6, 2020
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus NephritisYemil Atisha-Fregoso, Susan Malkiel, Kristina M Harris, et al.
Journal of the National Cancer Institute|June 30, 2014
Therapeutic targeting of integrin αvβ6 in breast cancerKate M Moore, Gareth J Thomas, Stephen W Duffy, et al.
Pageof 68